Spyre Therapeutics Files 8-K
Ticker: SYRE · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, name-change
Related Tickers: AAGL
TL;DR
Spyre Therapeutics (fka Aeglea) filed an 8-K, watch for updates.
AI Summary
On June 17, 2025, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K report. The filing indicates a change in the company's name and potentially other significant corporate events, as it is categorized under Regulation FD Disclosure and Other Events.
Why It Matters
This filing signals a significant corporate event for Spyre Therapeutics, potentially including a name change and other material disclosures that could impact investors.
Risk Assessment
Risk Level: medium — An 8-K filing often precedes or follows material events, requiring investors to monitor for further details.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former company name
- June 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 46-4312787 (ein) — IRS Employer Identification No.
- 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (address) — Principal Executive Offices
- 617 651-5940 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary reason for Spyre Therapeutics, Inc. filing this 8-K?
The 8-K filing is for a Current Report, indicating the reporting of significant corporate events, including Regulation FD Disclosure and Other Events, and potentially financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 17, 2025.
What was Spyre Therapeutics, Inc. formerly known as?
Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.
In which state is Spyre Therapeutics, Inc. incorporated?
Spyre Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Spyre Therapeutics, Inc.?
The business address is 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Spyre Therapeutics, Inc. (SYRE).